Blog
About

15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Present combination antiretroviral therapy (cART) alone does not cure HIV infection and requires lifelong drug treatment. The potential role of HIV therapeutic vaccines as part of an HIV cure is under consideration. Our aim was to assess the efficacy, safety, and immunogenicity of Vacc-4x, a peptide-based HIV-1 therapeutic vaccine targeting conserved domains on p24(Gag), in adults infected with HIV-1.

          Related collections

          Author and article information

          Journal
          Lancet Infect Dis
          The Lancet. Infectious diseases
          Elsevier BV
          1474-4457
          1473-3099
          Apr 2014
          : 14
          : 4
          Affiliations
          [1 ] Division of Infectious Diseases, UC Davis Medical Center, Sacramento, CA, USA.
          [2 ] Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik I, Immunologische Ambulanz, Bonn, Germany.
          [3 ] Division of Immunology and Allergy, Lausanne University Hospital, Lausanne, Switzerland.
          [4 ] Harrison Wing, St Thomas' Hospital, London, UK.
          [5 ] Department of Infectious Diseases, Ospedale San Raffaele and Vita-Salute University, Milan, Italy.
          [6 ] Infectious Diseases and AIDS Units, Hospital Clinic/IDIBAPS, University of Barcelona, Barcelona, Spain.
          [7 ] HIV Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain.
          [8 ] Universitätsklinikum Hamburg Eppendorf, Ambulanzzentrum Infektiologie, Hamburg, Germany.
          [9 ] EPIMED-Gesellschaft für Epidemiologische und Klinische Forschung in der Medizin mbH/Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany.
          [10 ] Department of Internal Medicine, Division of Infectious Diseases and Pulmonary Medicine, Charité-University Medicine Berlin, Berlin, Germany.
          [11 ] Irsicaixa Foundation, UAB, UVic, Hospital Universitari "Germans Trias i Pujol", Badalona, Catalonia, Spain.
          [12 ] Division of Infectious Diseases Cedars-Sinai Medical Center, Los Angeles, CA, USA.
          [13 ] UCLA CARE Center, University of California, Los Angeles, CA, USA.
          [14 ] Kobler Clinic, Chelsea and Westminster Hospital, London, UK.
          [15 ] ifi-Institut, an der Asklepios-Klinik St Georg, Hamburg, Germany.
          [16 ] Brighton and Sussex University Hospital, HIV/GUM Research, Elton John Centre, Brighton, UK.
          [17 ] Klinik I für Innere Medizin, Klinikum der Universität zu Köln, Cologne, Germany.
          [18 ] University of Miami School of Medicine AIDS Clinical Research Unit, Miami, FL, USA.
          [19 ] Division of Infectious Diseases, Northwestern University, Chicago, IL, USA.
          [20 ] Mericon AS, Skien, Norway.
          [21 ] Aptiv Solutions, Abingdon, UK.
          [22 ] SP PharmaConsulting, Uppsala, Sweden.
          [23 ] Bionor Laboratories, Skien, Norway.
          [24 ] Bionor Pharma ASA, Oslo, Norway.
          [25 ] Bionor Pharma ASA, Oslo, Norway. Electronic address: post@bionorpharma.com.
          Article
          S1473-3099(13)70343-8
          10.1016/S1473-3099(13)70343-8
          24525316

          Comments

          Comment on this article